Linezolid Treatment for Gram-Positive Infections: A Retrospective Comparison with Teicoplanin

被引:12
|
作者
Tascini, C. [1 ]
Gemignani, G.
Doria, R.
Biancofiore, G. [2 ]
Urbani, L. [3 ]
Mosca, C. [4 ]
Malacarne, P. [5 ]
Papineschi, F. [6 ]
Passaglia, C. [7 ]
Dal Canto, L. [8 ]
Procaccini, M.
Furneri, G.
Didoni, G.
Filipponi, F. [3 ]
Menichetti, F.
机构
[1] Univ Pisana, Azienda Osped, Osped Cisanello, UO Malattie Infett,Infect Dis Unit, I-56100 Pisa, Italy
[2] Univ Pisana, Azienda Osped, Liver Transplant Intens Care Unit, I-56100 Pisa, Italy
[3] Univ Pisana, Azienda Osped, Liver Transplant Unit, I-56100 Pisa, Italy
[4] Univ Pisana, Azienda Osped, Intens Care Unit 4, I-56100 Pisa, Italy
[5] Univ Pisana, Azienda Osped, Intens Care Unit 2, I-56100 Pisa, Italy
[6] Univ Pisana, Azienda Osped, Ematol Unit, I-56100 Pisa, Italy
[7] Univ Pisana, Azienda Osped, Med Div 4, I-56100 Pisa, Italy
[8] Univ Pisana, Azienda Osped, Pharm Unit, I-56100 Pisa, Italy
关键词
Linezolid; teicoplanin; Gram-positive bacterial infection; length of stay; MRSA; SOFT-TISSUE INFECTIONS; BACTERIAL-INFECTIONS; DOUBLE-BLIND; VANCOMYCIN; PNEUMONIA; MULTICENTER; OUTCOMES; TRIAL; SKIN;
D O I
10.1179/joc.2009.21.3.311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In randomized studies linezolid, indicated for Gram-positive infections, was as effective as teicoplanin in critical ill patients or was superior to teicoplanin in skin infection, pneumonia and bacteremia. We performed a 2-year comparative, retrospective study of patients treated with linezolid or teicoplanin in a single hospital for the same indications. We collected information about the type of infection, the responsible pathogen, therapy administered before study drugs, antibiotic associated with the study drugs, length of hospital stay (LOS), adverse events and outcome of the infections. The aim of the study was to evaluate the efficacy of linezolid in this retrospective patients series. Overall we identified 169 patients treated with linezolid and 91 with teicoplanin. Response to therapy, (resolution or improvement of infection) was better in patients treated with linezolid compared to teicoplanin (83.9% versus 69.2%. p=0.002). Response to therapy by type of pathogen showed the superior efficacy of linezolid against Staphylococcus aureus (including MRSA) and enterococci; although not statistically significant because of the small number of patients enrolled, they were close to significance (p<0.056 for S. aureus, p<0.055 for MRSA, p<0.061 for enterocococi). Overall LOS in linezolid-treated patients was 4.6 days (p<0.041) less. Empirical use of linezolid reduced LOS by 6 days (p<0.038), especially in VAP and bacteremia patients (p<0.05). Mortality due to infection was 9.8% in both groups, and adverse events were most frequently documented in linezolid-treated patients. Linezolid was clinically superior to teicoplanin in the treatment of Gram-positive infections.
引用
收藏
页码:311 / 316
页数:6
相关论文
共 50 条
  • [21] Pharmacoeconomic Evaluation of Linezolid Versus Teicoplanin in Bacteremia by Gram-Positive Microorganisms*
    Santiago Grau
    Javier Mateu-de Antonio
    Javier Soto
    Mónica Marín-Casino
    Esther Salas
    Pharmacy World and Science, 2005, 27 : 459 - 464
  • [22] Linezolid - A synthetic oxazolidinone antimicrobial for treatment of serious gram-positive infections
    Cupo-Abbott, J
    Louie, SG
    Rho, JP
    FORMULARY, 2000, 35 (06) : 483 - +
  • [23] Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by gram-positive microorganisms
    Grau, S
    Mateu-de Antonio, J
    Soto, J
    Marín-Casino, M
    Salas, E
    PHARMACY WORLD & SCIENCE, 2005, 27 (06): : 459 - 464
  • [24] TEICOPLANIN FOR THERAPY OF GRAM-POSITIVE INFECTIONS IN NEUTROPENIC PATIENTS
    VERHAGEN, C
    DEPAUW, BE
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1987, 7 (06) : 491 - 498
  • [25] TEICOPLANIN IN THE TREATMENT OF GRAM-POSITIVE BACTEREMIA AND ENDOCARDITIS
    CRUCIANI, M
    CONCIA, E
    DIPERRI, G
    ADAMI, T
    NAVARRA, A
    FENDT, D
    DESTRO, G
    MARONE, P
    SOLBIATI, M
    BASSETTI, D
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1992, 51 (05): : 704 - 714
  • [26] Management of Gram-positive infections with linezolid in immunocompromized patients
    Lalayanni, C.
    Neokleous, N.
    Stavroyianni, N.
    Sirigou, A.
    Karpouza, A.
    Papalexandri, A.
    Bitsioni, A.
    Smias, C.
    Saloum, R.
    Fassas, A.
    Anagnostopoulos, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 458 - 458
  • [27] Teicoplanin Therapeutic Drug Monitoring and Treatment Outcomes in Children With Gram-Positive Infections
    Loane, Georgia
    Gwee, Amanda
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2021, 10 (05) : 682 - 685
  • [28] CLINICAL-EVALUATION OF TEICOPLANIN IN THE TREATMENT OF GRAM-POSITIVE BACTERIAL INTRAVASCULAR INFECTIONS
    LIVORNESE, LL
    GOLD, M
    JOHNSON, CC
    MEASLEY, R
    KAYE, D
    KORZENIOWSKI, O
    WALSH, ML
    SAMEL, C
    HESSEN, M
    LEVISON, ME
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (01) : 188 - 191
  • [29] Cost effectiveness analysis of linezolid vs. teicoplanin for the treatment of serious gram-positive bacterial infections in a multinational randomized trial
    Li, JZ
    Willke, RJ
    Balan, DA
    Nathwani, D
    López, H
    Rittenhouse, BE
    Tavacoli, M
    Mozaffari, E
    VALUE IN HEALTH, 2003, 6 (03) : 259 - 260
  • [30] TREATMENT OF INFECTIONS BY STAPHYLOCOCCI AND OTHER GRAM-POSITIVE BACTERIA WITH TEICOPLANIN - AN OPEN STUDY
    PAULUZZI, S
    DELFAVERO, A
    MENICHETTI, F
    BARATTA, E
    MORETTI, VM
    DIFILIPPO, P
    PASTICCI, MB
    GUERCIOLINI, R
    PATOIA, L
    FRONGILLO, RF
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 (03) : 431 - 438